NAGE vs. ADMA
NAGE (Niagen Bioscience, Inc) and ADMA (ADMA Biologics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, NAGE returned 1.58%/yr vs 2.29%/yr for ADMA. At a 0.18 correlation, their price movements are largely independent.
Performance
NAGE vs. ADMA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NAGE achieves a -46.86% return, which is significantly higher than ADMA's -52.36% return. Over the past 10 years, NAGE has underperformed ADMA with an annualized return of 1.58%, while ADMA has yielded a comparatively higher 2.29% annualized return.
NAGE
- 1D
- -0.88%
- 1M
- -7.65%
- YTD
- -46.86%
- 6M
- -48.08%
- 1Y
- -75.22%
- 3Y*
- 27.26%
- 5Y*
- -18.04%
- 10Y*
- 1.58%
ADMA
- 1D
- 1.40%
- 1M
- 5.46%
- YTD
- -52.36%
- 6M
- -55.41%
- 1Y
- -51.37%
- 3Y*
- 30.95%
- 5Y*
- 39.41%
- 10Y*
- 2.29%
NAGE vs. ADMA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NAGE Niagen Bioscience, Inc | -46.86% | 19.89% | 270.98% | -14.88% | -55.08% | -22.08% | 11.37% | 25.66% | -41.67% | 77.64% |
ADMA ADMA Biologics, Inc. | -52.36% | 6.36% | 279.42% | 16.49% | 175.18% | -27.69% | -51.25% | 67.36% | -25.55% | -37.30% |
Correlation
The correlation between NAGE and ADMA is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Oct 17, 2013 | 0.18 |
The correlation between NAGE and ADMA shifts across timeframes, from 0.18 (all time) to 0.28 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
NAGE:
$285.83M
ADMA:
$2.09B
NAGE:
$0.22
ADMA:
$0.68
NAGE:
15.50
ADMA:
12.84
NAGE:
2.22
ADMA:
4.16
NAGE:
3.47
ADMA:
5.34
NAGE:
$130.42M
ADMA:
$509.86M
NAGE:
$83.83M
ADMA:
$312.42M
NAGE:
$13.37M
ADMA:
$218.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NAGE vs. ADMA — Risk / Return Rank
NAGE
ADMA
NAGE vs. ADMA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Niagen Bioscience, Inc (NAGE) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NAGE | ADMA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.54 | ||
| Sortino ratioReturn per unit of downside risk | -1.64 | ||
| Omega ratioGain probability vs. loss probability | 0.65 | 0.82 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | -0.98 | -0.82 | -0.16 |
| Martin ratioReturn relative to average drawdown | -1.37 | -1.64 | +0.27 |
Loading charts...
Drawdowns
NAGE vs. ADMA - Drawdown Comparison
The maximum NAGE drawdown since its inception was -97.00%, which is greater than ADMA's maximum drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for NAGE and ADMA.
Loading charts...
Drawdown Indicators
| NAGE | ADMA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.00% | -91.28% | -5.72% |
Max Drawdown (1Y)Largest decline over 1 year | -76.61% | -62.71% | -13.90% |
Max Drawdown (3Y)Largest decline over 3 years | -76.61% | -68.99% | -7.62% |
Max Drawdown (5Y)Largest decline over 5 years | -88.57% | -68.99% | -19.58% |
Max Drawdown (10Y)Largest decline over 10 years | -93.65% | -86.11% | -7.54% |
Current DrawdownCurrent decline from peak | -81.96% | -64.55% | -17.41% |
Average DrawdownAverage peak-to-trough decline | -75.72% | -53.07% | -22.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.03% | 31.44% | +23.59% |
Volatility
NAGE vs. ADMA - Volatility Comparison
Niagen Bioscience, Inc (NAGE) has a higher volatility of 12.88% compared to ADMA Biologics, Inc. (ADMA) at 10.26%. This indicates that NAGE's price experiences larger fluctuations and is considered to be riskier than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NAGE | ADMA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.88% | 10.26% | +2.62% |
Volatility (6M)Calculated over the trailing 6-month period | 34.55% | 45.76% | -11.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 50.52% | 54.14% | -3.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.86% | 59.49% | +17.37% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.72% | 69.07% | +9.65% |
Dividends
NAGE vs. ADMA - Dividend Comparison
Neither NAGE nor ADMA has paid dividends to shareholders.
Financials
NAGE vs. ADMA - Financials Comparison
This section allows you to compare key financial metrics between Niagen Bioscience, Inc and ADMA Biologics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NAGE vs. ADMA - Profitability Comparison
NAGE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported a gross profit of 19.98M and revenue of 31.47M. Therefore, the gross margin over that period was 63.5%.
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.
NAGE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported an operating income of 1.58M and revenue of 31.47M, resulting in an operating margin of 5.0%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.
NAGE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported a net income of 6.32M and revenue of 31.47M, resulting in a net margin of 20.1%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.
Frequently Asked Questions
NAGE and ADMA have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NAGE has higher volatility (12.88%) compared to ADMA (10.26%). In terms of maximum drawdown, NAGE dropped -97.00% vs ADMA's -91.28%.
ADMA currently has the higher Sharpe Ratio (-0.95 vs -1.49), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NAGE and ADMA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer